Quantum-Si 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Quantum-Si reported 3rd quarter 2026 revenue of $212,000, compared with $552,000 in the 3rd quarter of 2025; revenue for the first 9 months of 2026 was $814,000, compared with $2 million in the prior year period.
- 3rd quarter 2026 gross profit was $74,000, with a 35% gross margin; first 9 months gross profit was $320,000, with a 39% gross margin.
- 3rd quarter GAAP total operating expenses were $23.9 million, compared with $40 million in the prior year quarter, and adjusted operating expenses were $18.2 million, compared with $21.4 million.
- For the first 9 months of 2026, GAAP total operating expenses were $73.8 million and adjusted operating expenses were $62.1 million, compared with $96 million and $68.1 million, respectively, in the prior year period.
- 3rd quarter 2026 net loss was $22.3 million, compared with $35.7 million in the prior year quarter; adjusted EBITDA was negative $17 million, compared with negative $20.1 million.
- As of September 30th, 2026, Quantum-Si had $149.4 million in cash, cash equivalents, and investments in marketable securities, which management said was sufficient to fund operations into the 4th quarter of 2028.
- Management said the additional Proteus instrument design cycle is proceeding as planned, design activities are complete, major components have been released and ordered, and subassembly manufacturing is underway.
- The company said it believes it has substantially addressed previously identified instrument variability issues, with consistent performance across its internal fleet; first instruments from the current build cycle are expected during the current quarter.
- Quantum-Si has demonstrated detection of the 18th and 19th amino acids and expects to demonstrate the 20th before the end of the year; its commercially available sequencing kits supported detection of 15 amino acids at the end of 2025.
- At World Hupo, a developmental Proteus version with interim chemistry capable of detecting 18 amino acids delivered approximately 30 times more sequencing output per chamber than Platinum Pro and a 1.36% false discovery rate, compared with 6.58% on Platinum Pro.
- Proteus identified all proteins in both a 10-plex and 24-plex reference mixture while generating deeper peptide coverage and greater overall amino acid content.
- Since announcing the Proteus Roadshow in April, the company has held events in more than 35 cities and reached more than 800 attendees across the United States, Canada, and Europe; it has also launched a Proteus preorder program.
- The restructuring actions announced in August have been implemented, and management said they have not adversely affected Proteus development.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Quantum-Si third quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Risa Lindsay.
Please go ahead. Good afternoon, everyone, and thank you for joining us.
Earlier today, Quantum-Si released financial results for the third quarter and nine months ended September 30, 2026. A copy of the press release is available on the company's website. Joining me today are Jeff Hawkins, our President and Chief Executive Officer, as well as Jeff Keyes, our Chief Financial Officer. Before we begin, I would like to remind you that management will be making certain forward-looking statements within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements of our press release. For a more complete list and description of risk factors, please see the company's filings made with the Securities and Exchange Commission.
This conference call contains time-sensitive information that is accurate only as of the live broadcast date, today, November 5, 2026, at 1:30 P.M. Pacific Time. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with U.S. generally accepted accounting principles, or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release filed earlier today. With that, let me turn the call over to Jeff Hawkins.
Good afternoon, and thank you for joining us. On today's call, we will provide a business update and review our operating results for the third quarter of 2026. After that, we will open the call for questions. The call will be organized around our three corporate priorities for 2026, which are as follows: to deliver Proteus with the capabilities customers need, to prepare the market for Proteus launch, and to preserve our financial strength. Our first priority is to deliver Proteus with the capabilities customers need. First, let's start by diving a bit deeper into the Proteus instrument development program. Last quarter, we discussed our decision to add an additional integrated instrument design cycle before moving into production. That decision was driven by our desire to further reduce manufacturing risk, improve system repeatability, and ensure a positive customer experience at launch.
Since then, we have made strong progress across several fronts. Most importantly, based on the recent performance data generated, including the data presented at World HUPO in September, we believe we have substantially addressed the instrument variability issues that were identified earlier in the development process. The consistency and quality of the sequencing data generated from our integrated units are encouraging and support our confidence in the underlying instrument architecture. We have also made meaningful progress on the instrument design cycle itself. As the work advanced during the quarter, we were able to significantly limit the number of design changes required relative to our original expectations. We view this as an important outcome because it both reduces risk within the current design cycle and increases our confidence as we move toward future manufacturing builds. Design activities are now complete.
All major components have been released and ordered, manufacturing of sub-assemblies is underway, and we expect to begin receiving the first instruments from this build cycle during the current quarter. In addition, given the reduced scope of design changes and the encouraging performance data we have generated, we have begun parallel tracking select production readiness activities. These efforts include long lead component procurement and other manufacturing preparation work intended to support an efficient transition into production. As many of you are aware, supply chain planning is an increasingly important focus area for all companies in the current AI-driven procurement environment, and we believe taking these steps now appropriately balances risk reduction with cost and maintaining development momentum. Overall, we are encouraged by the progress we have made.
The additional instrument cycle is proceeding as planned, performance continues to improve, and we believe we are taking the right steps to further de-risk the platform as we move toward our commercial launch in the second quarter of 2027. Turning now to recognizer development. Since our last earnings call, we demonstrated detection of the 18th and 19th amino acids. Additionally, we incorporated detection of the 18th amino acid into a developmental sequencing kit, which was used to successfully generate data presented at World HUPO. Based on the progress we have made and the pace of advancement we are seeing, we believe we are well-positioned to demonstrate detection of the 20th amino acid before the end of the year. What is particularly encouraging is not just the number of amino acids we have added, but the increasing rate at which we are able to develop new recognizers.
The protein engineering capabilities and infrastructure established over the past several years are now translating into substantially faster development cycles, enabling us to expand coverage at a pace that materially exceeds what we have achieved historically. To put that progress in perspective, our commercially available sequencing kit supported detection of 15 amino acids at the end of 2025. Today, we have demonstrated 19 amino acids, with the 20th now within reach. We believe this acceleration reflects the growing maturity of the platform, the value of the underlying proprietary training data we have generated, and the increasing efficiency of our recognizer development process. Before moving to library preparation, I want to briefly touch on our AI initiatives within our algorithm development team.
Over the past quarter, we had rapidly transitioned from the traditional rules-based analysis approaches used on Platinum Pro today to incorporating AI and machine learning throughout our data analysis pipeline. We believe this represents a significant inflection point for the platform, with the potential to extract substantially more information from our sequencing data while improving overall performance and data quality. As we discussed at World HUPO, we believe the combination of AI-driven analysis and detection of all 20 amino acids creates a path toward delivering reference-free sequencing in 2027. While this work remains in development, the results we have seen to date are highly encouraging, and we look forward to sharing more details as we move closer to launch. Finally, I want to provide an update on our library preparation strategy. As a reminder, library preparation is the process used to prepare a customer's sample for sequencing.
Historically, we approached library preparation as a generic solution designed to work across a wide range of proteins and applications. Through both our internal development efforts and our experience supporting Platinum customers, we have continued to expand our understanding of how proteins behave during sample preparation and how library preparation can be optimized for different research objectives. Building on those learnings, our team is actively advancing multiple library preparation innovations focused on improving protein coverage and enabling deeper characterization of proteoforms. We are excited by the progress we have made and expect to complete the current phase of technology development by the end of this year. We believe these advances have the potential to significantly expand the range of applications that can be addressed on our platform and further enhance the value of Proteus for customers pursuing increasingly complex biological questions.
Upon completion of this development phase, we expect to be in a position in early 2027 to outline a more comprehensive library preparation product roadmap for 2027 and beyond, including how application-specific workflows and kits can be deployed individually or in combination to optimize performance across different use cases. We increasingly view library preparation not simply as a sample preparation step, but as a strategic component of the overall workflow. As we continue to advance these capabilities, we believe they will play an important role in increasing protein coverage, enabling deeper proteoform characterization, and expanding the addressable applications of the Proteus platform. Our second corporate priority is to prepare the market for Proteus launch. In September, we attended World HUPO in Singapore. During the conference, we presented a direct comparison between Proteus and Platinum Pro.
The data presented at World HUPO was generated using a developmental version of Proteus, including an interim chemistry capable of detecting 18 amino acids. While development remains ongoing, the results provide an early indication of the performance trajectory we are seeing as we advance towards commercialization. While we are very pleased with the World HUPO results, we firmly believe the Proteus platform will ultimately launch with meaningfully exceed the performance demonstrated in this interim study. First, Proteus delivered approximately 30 times more sequencing output per chamber than Platinum Pro, demonstrating that the performance gains extend beyond the increase in well count alone. Second, the quality of sequencing results from Proteus also exceeded Platinum Pro. The interim results demonstrated Proteus had a 1.36% false discovery rate compared to 6.58% on Platinum Pro. This represented an approximately 80% reduction in false discovery rate versus Platinum Pro.
Third, Proteus successfully identified all proteins contained within both a 10-plex and 24-plex reference mixture while simultaneously generating deeper peptide coverage and greater overall amino acid content. Next, I want to provide an update on our commercial initiatives to build awareness of Proteus in advance of launch. Our commercial team has been executing well, and we continue to receive very positive feedback on Proteus and the wide range of applications it is designed to address. Since announcing the Proteus Roadshow in April, we have completed events in more than 35 cities, reaching more than 800 attendees across the U.S., Canada, and Europe. These events are designed to educate prospective users, expand awareness of single-molecule protein sequencing, and build our commercial pipeline ahead of launch.
We continue to see strong attendance and engagement, and the positive reception to the new World HUPO data has further increased customer interest in learning more about the platform. Based on customer feedback and the positive reception to the World HUPO data, we recently launched our Proteus pre-order program. The program is designed to help customers plan for adoption and secure priority pricing and access to the platform following commercial launch. While still early, we are encouraged by the level of customer engagement and the quality of discussions underway with prospective customers. Our third priority is to preserve our financial strength. The restructuring actions announced in August have now been implemented and are achieving their intended objectives. We have aligned our expense base with the revised Proteus timeline while preserving the resources and capabilities required to execute the program successfully. Importantly, the actions have not adversely impacted Proteus development.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
